ONC206 for Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023)
Conditions: Diffuse Midline Glioma (DMG); Malignant Brain Tumors; Glioblastoma; Recurrent Ependymoma; Recurrent Malignant Brain Neoplasm; Spinal Cord Glioma; WHO Grade III Glioma Interventions: Drug: ONC206; Radiation: Standard of Care Radiation Therapy Sponsors: Sabine Mueller, MD, PhD; Oncoceutics, Inc.; Mithil Prasad Foundation; Storm the Heavens Fund; The ChadTough Defeat DIPG Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2021 Category: Research Source Type: clinical trials
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Conditions: Ependymoma; Ewing Sarcoma; High-grade Glioma; Leukemia and Lymphoma; Medulloblastoma; Miscellaneous Brain Tumors; Miscellaneous Solid Tumors; Neuroblastoma; Relapsed, Refractory Malignant Neoplasms; Rhabdomyosarcoma Interventions: Biological: Nivolumab; Biological: NKTR-214 Sponsors: Bristol-Myers Squibb; Nektar Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2021 Category: Research Source Type: clinical trials
